

FORM PTO-1390 (Modified)
(REV 10-95)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

196811US0PCT

DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/623596

INTERNATIONAL APPLICATION NO.
PCT/JP99/01084INTERNATIONAL FILING DATE
05 March 1999PRIORITY DATE CLAIMED
06 March 1998

TITLE OF INVENTION

A GENE CODING FOR PENICILLIN BINDING PROTEIN AND A METHOD FOR PRODUCING L-GLUTAMIC ACID

APPLICANT(S) FOR DO/EO/US

Masaaki WACHI, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☐ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Request for Consideration of Documents Cited in International Search Report

Notice of Priority

Drawings (1 sheet)

Sequence Listing (13 pages)

09/623596

526 Rec'd PCT/PTC 05 SEP 2000

196811US-8222-10-0 PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
MASAKI WACHI ET AL : ATTN: APPLICATION DIVISION
SERIAL NO: NEW PCT APPLICATION :
(Based on PCT/JP99/01084)
FILED: HEREWITH :
FOR: A GENE CODING FOR :
PENICILLIN BINDING PROTEIN
AND A METHOD FOR PRODUCING
L-GLUTAMIC ACID

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

SIR:

Prior to examination on the merits, please amend the above-identified application as follows.

IN THE CLAIMS

Please amend the claims as follows:

Claim 5, lines 1-2, replace "any one of claims 1-4" with --claim 1--.

Claim 6, lines 1-2, replace "any one of claims 1-4" with --claim 1--.

REMARKS

Claims 1-9 are active in the present application. The claims are amended for clarity and to remove multiple dependencies. No new matter has been added. Applicants submit that the present application is now in condition for examination on the merits. Early notification of such is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Attorney of Record
Registration No. 24,618

Daniel J. Pereira, Ph.D.
Registration No. 45,518



22850

(703) 413-3000
Fax #: (703) 413-2220
NFO/DJP/law

I:\user\DJPER\196811US-pr.wpd

1/PR#
1

09/623596
526 Rec'd PCT/PTO 05 SEP 2000

SPECIFICATION

A Gene Coding for Penicillin Binding Protein and a Method for Producing L-Glutamic Acid

5

Technical Field

10 The present invention relates to a method for
producing L-glutamic acid by fermentation. L-glutamic
acid is widely used as a raw material of seasonings and
so forth.

Background Art

15 If coryneform bacteria are cultured in a medium
containing a restricted amount of biotin, the bacteria
produce a marked amount of L-glutamic acid. On the
other hand, if coryneform bacteria are cultured in a
medium containing an excessive amount of biotin, the
20 bacteria do not produce L-glutamic acid. However, it is
known that, even under such a condition, if a surface
active agent or a biotin activity suppressor such as
penicillin is added to the medium, growth of the
bacteria is suppressed and they become to produce a
25 marked amount of L-glutamic acid.

The glutamic acid production induced by addition
of penicillin to a medium has been studied for many

years (T.D. Nunheimer, J. Birnbaum, E.D. Ihnen and A.L. Demasin, *Appl. Microbiol.*, 20, 215-217 (1970)). The effect of penicillin is considered to cause structural change of cellular surface layers, thereby enhancing permeability of cytoplasmic membranes for glutamic acid.

In addition, it has also been studied through what kind of mechanism the restriction of the biotin amount or the addition of a surface active agent or penicillin influences the productivity of L-glutamic acid of coryneform bacteria, and presence of a gene considered to participate in the L-glutamic acid production has been elucidated (*dtsR* gene). Further, it has been confirmed that a strain of which *dtsR* gene is disrupted produces a marked amount of L-glutamic acid even under a condition in which biotin is present in such an amount that a wild strain hardly produces L-glutamic acid (International Patent Publication WO95/23224).

Furthermore, there have been obtained many findings that contradicts the explanation that the glutamic acid production is induced the enhancement of permeability of cytoplasmic membranes, and the mechanism of the glutamic acid production induced by penicillin has still been unknown (E. Kimura, Y. Kawahara and W. Nakamatsu, *Tanpakusshitu Kakusan Koso (Protein, Nucleic acid and Enzyme)*, vol. 42, pp.2633-2640 (1997)).

By the way, it is well known that penicillin binding proteins (PBPs) play an important role in

bacterial cell division. The penicillin binding proteins are considered to be enzymes that exist in bacterial cellular surface layers, and they specifically bind to β -lactam antibiotics such as penicillin.

5 Although it may vary depending on the species, it is considered that 3-8 kinds of the proteins are usually found in *Escherichia coli*, and their molecular weights are distributed around the range of 40,000-120,000. Penicillin inhibits the enzymatic reactions by binding
10 to a serine residue of an active site of the penicillin binding proteins.

It has been elucidated that 7 kinds of penicillin binding proteins exist in *Escherichia coli* (*E. coli*), which was especially a main target of researches (B.G. Spratt, *Proc. Natl. Acad. Sci. U.S.A.*, 72, 2999 (1975)).
15 Among those, those designated as PBP2 and PBP3 have been demonstrated to play an important role in cell division (B.G. Spratt, *J. Bacteriol.*, 131, 293 (1977)). However, it has not been known whether penicillin binding
20 proteins exists in coryneform bacteria.

Disclosure of the Invention

The inventors of the present invention
25 investigated whether penicillin binding proteins (abbreviates as "PBPs" hereinafter) should exist also in coryneform bacteria, and analyzed their functions. As a

result, the inventors obtained a novel finding considered to be useful for elucidating the mechanism of the glutamic acid production in coryneform bacteria induced by penicillin, and at the same time, they found that the finding could be utilized for developments concerning the improvement of glutamic acid producing ability of coryneform bacteria from a viewpoint that had not been known yet.

The present invention was accomplished on the basis of the aforementioned findings, and it relates to a method for producing L-glutamic acid, comprising the steps of cultivating a coryneform bacterium in a liquid medium to produce and accumulate L-glutamic acid in the medium, and collecting the L-glutamic acid, wherein PBP does not normally function in the bacterium and the bacterium has the ability to produce L-glutamic acid

In a preferred embodiment of the present invention, the coryneform bacterium used in the aforementioned method is a bacterium in which PBP functions normally at the first temperature and does not function normally at the second temperature, and the method comprises a step of cultivating the bacterium at the first temperature to proliferate the bacterium and a step of cultivating the bacterium at the second temperature to produce L-glutamic acid.

In another embodiment of the present invention, the coryneform bacterium used in the aforementioned

method is a bacterium which harbors a plasmid containing a gene coding for PBP (PBP gene) and a temperature sensitive replication control region, and in which the PBP gene on chromosome does not function, and the plasmid can replicate at the first temperature, and cannot replicate at the second temperature.

In a further embodiment of the present invention, PBP produced by the coryneform bacterium used in the method has a temperature sensitive mutation.

In a still further embodiment of the present invention, PBP shows a molecular weight of about 60,000 in SDS-polyacrylamide gel electrophoresis, when PBP binds to penicillin G.

The second aspect of the present invention is DNA which codes for a protein defined in the following (A) or (B):

(A) a protein which has the amino acid sequence of SEQ ID NO: 2 in Sequence Listing;

(B) a protein which has an amino acid sequence of SEQ ID NO: 2 in Sequence Listing including substitution, deletion, insertion, addition or inversion of one or several amino acids, and an activity for binding to penicillin.

In a preferred embodiment of the invention, the aforementioned DNA is DNA defined in the following (a) or (b):

(a) DNA which comprises at least the nucleotide

sequence of the nucleotide numbers 881 to 2623 of SEQ ID NO: 1 in Sequence Listing;

(b) DNA which is hybridizable with a nucleotide sequence comprising at least the sequence of the nucleotide numbers 881 to 2623 of SEQ ID NO: 1 in Sequence Listing under a stringent condition, and codes for a protein having an activity for binding to penicillin.

Hereafter, the present invention will be explained in detail.

<1> PBP of coryneform bacteria

In the present invention, coryneform bacteria include those bacteria having been hitherto classified into the genus *Brevibacterium* but united into the genus *Corynebacterium* at present (*Int. J. Syst. Bacteriol.*, 41, 255 (1981)), and include bacteria belonging to the genus *Brevibacterium* closely relative to the genus *Corynebacterium*. Examples of such coryneform bacteria are listed below.

Corynebacterium acetoacidophilum

Corynebacterium acetoglutamicum

Corynebacterium callunae

Corynebacterium glutamicum

Corynebacterium lilium (*Corynebacterium glutamicum*)

Corynebacterium melassecola

- Brevibacterium divaricatum*
 (*Corynebacterium glutamicum*)
Brevibacterium flavum (*Corynebacterium glutamicum*)
Brevibacterium immariophilum
 5 *Brevibacterium lactofermentum*
 (*Corynebacterium glutamicum*)
Brevibacterium roseum
Brevibacterium saccharolyticum
Brevibacterium thiogenitalis
 10 *Corynebacterium thermoaminogenes*

Specifically, the following strains can be exemplified.

- Corynebacterium acetoacidophilum* ATCC 13870
 15 *Corynebacterium acetoglutamicum* ATCC 15806
Corynebacterium callunae ATCC 15991
Corynebacterium glutamicum ATCC 13020
Corynebacterium lilium (*Corynebacterium glutamicum*) ATCC 15990
 20 *Corynebacterium melassecola* ATCC 17965
Brevibacterium divaricatum
 (*Corynebacterium glutamicum*) ATCC 14020
Brevibacterium flavum (*Corynebacterium glutamicum*)
 ATCC 14067
 25 *Brevibacterium immariophilum* ATCC 14068
Brevibacterium lactofermentum
 (*Corynebacterium glutamicum*) ATCC 13869

Brevibacterium roseum ATCC 13825

Brevibacterium saccharolyticum ATCC 14066

Brevibacterium thiogenitalis ATCC 19240

Corynebacterium thermoaminogenes AJ12340

5 (FERM BP-1539)

PBP referred to in the present invention is a membrane protein that exists in the cellular surface layers of the above coryneform bacteria, and if it
10 contacts with penicillin, it binds thereto with a covalent bond. PBP can be detected by, for example, adding labeled penicillin to a membrane fraction of coryneform bacteria to allow a reaction, subjecting a surface active agent-soluble fraction to electrophoresis
15 on polyacrylamide gel, and visualizing the label (penicillin binding test). As shown in the examples mentioned below, PBPs of *Brevibacterium lactofermentum* are detected as three bands at molecular weights of about 110 kDa, 100 kDa and 60 kDa in SDS polyacrylamide
20 gel electrophoresis (SDS-PAGE) in a state that they bind to penicillin G, and they were designated as PBP1, PBP2 and PBP3.

When affinity between these PBPs and mecillinam, which is a derivative of penicillin G, was investigated,
25 it was found that mecillinam selectively binds to PBP3. Further, it was found that, when *Brevibacterium lactofermentum* was cultured under a condition that

biotin was present in a significant amount, L-glutamic acid was produced in the presence of a certain concentration of mecillinam. These facts suggested that L-glutamic acid production could be induced in the presence of a significant amount of biotin by inhibiting the function of PBPs, at least PBP3. Therefore, a coryneform bacterium in which PBP does not normally function should come to be able to induce L-glutamic acid production without addition of a biotin activity suppressor even in the presence of a significant amount of biotin. Moreover, there is possibility that such a coryneform bacterium in which PBP does not normally function should have improved L-glutamic acid producing ability. Furthermore, a novel finding concerning the L-glutamic acid production of coryneform bacteria should be obtained by manipulating a PBP gene, and it can be utilized for development from an aspect that have not been known yet.

In the present invention, the expression "PBP does not normally function" means a state that the L-glutamic acid production is induced in the presence of a significant amount of biotin. It may be a state that PBP is not produced because of inhibition of transcription or translation of a PBP gene, or a state that the function of PBP is reduced or eliminated because of a mutation occurring in the produced PBP.

<2> Coryneform bacterium in which PBP does not function normally

The coryneform bacterium used for the method for producing of L-glutamic acid according to the present invention is a coryneform bacterium in which PBP does not function normally. In a preferred embodiment, the coryneform bacterium used in the aforementioned method is a bacterium in which PBP functions normally under the first culture condition and does not function normally under the second culture condition. Such a coryneform bacterium can proliferate under the first culture condition, and can produce L-glutamic acid under the second culture condition in the presence of a significant amount of biotin. As PBP, PBP3 is preferred.

As the aforementioned culture condition, there can be mentioned temperature of culture, osmotic pressure of medium, pH, components of medium and so forth. Examples of the components of medium include an inducer such as IPTG (isopropyl- β -D-thiogalactopyranoside) and acetic acid, and a suppressor such as glucose. The culture temperature will be explained as an example of the culture condition in the description hereinafter. However, concerning other culture conditions, the term "temperature" in the following description can be replaced with a term indicating another condition.

As an example of the coryneform bacterium in which PBP does not function normally, there can be mentioned a

mutant strain in which a mutation is introduced into a gene coding for PBP (PBP gene) so that PBP that functions normally should not be expressed. The aforementioned mutation may be a mutation that inhibits transcription or translation of the PBP gene, or a mutation that produces PBP that does not function normally.

Since a mutation that causes complete deficiency of PBP should be fatal to the bacteria, the aforementioned mutant strain can be obtained as a conditional mutant strain such as a temperature sensitive mutant strain. Such a mutant strain can be obtained by, for example, treating a coryneform bacterium by ultraviolet irradiation or with a chemical agent to obtain mutant strains that can proliferate at the first temperature (for example, low temperature) but cannot proliferate at the second temperature (for example, high temperature), and selecting, from the obtained mutant strains, a mutant strain that can proliferate at the first temperature and produces L-glutamic acid in the presence of a significant amount of biotin when it is cultured at the second temperature. As a mutant strain that represents such a characteristic, a DTSR protein deficient strain (International Patent Publication WO95/23224) or an α -KGDH deficient strain (International Patent Publication WO95/34672) may be selected. However, it can be confirmed if a candidate

strain is a mutant strain having a mutation concerning PBP by performing the aforementioned penicillin binding test for the cells cultured at the second temperature.

5 If such a mutant strain is once obtained, a PBP gene of the coryneform bacterium can be cloned by using the mutant strain as a host. That is, a DNA fragment containing a PBP gene can be obtained by transforming the mutant strain in which PBP does not function normally with a plasmid containing chromosomal DNA
10 derived from coryneform bacteria, selecting a transformant strain in which PBP functions normally, and collecting the plasmid.

Techniques used for usual gene recombination such as those for digestion and ligation of DNA,
15 transformation, extraction of recombinant DNA from transformants, colony hybridization and so forth are described in references well known to those skilled in the art, for example, J. Sambrook, E.F. Fritsch, and T. Maniatis, Molecular Cloning, Cold Spring Harbor
20 Laboratory Press (1989) and so forth.

A chromosomal DNA library can be produced, for example, as follows. First, chromosomal DNA is prepared by the method of Miura et al. (H. Saito, and K. Miura, Biochem. Biophys. Acta, 72, 619 (1963)) or the like.
25 Then, the chromosomal DNA is partially digested with a suitable restriction enzyme to obtain a mixture of various fragments. If the degree of the digestion is

controlled by adjusting digestion reaction time or the like, restriction enzymes of a wide range can be used. For example, the chromosomal DNA is digested by allowing *Sau3AI* to act on it at a temperature of 30°C or higher, preferably 37°C or higher, for various periods of time (1 minute to 2 hours) at an enzyme concentration of 1-10 units/ml.

Subsequently, the digested chromosomal DNA fragments are ligated to vector DNA autonomously replicable within *Escherichia coli* cells to produce recombinant DNA. More specifically, a restriction enzyme producing the same end nucleotide sequence as the restriction enzyme used for the digestion of the chromosomal DNA, *Sau3AI*, for example, *BamHI*, is allowed to act on the vector DNA at a temperature of 30°C or higher for 1 hour or more, preferably 1-3 hours, at an enzyme concentration of 1-100 units/ml to fully digest the vector and cleave it. Then, the mixture of the chromosomal DNA fragments and the cleaved vector DNA obtained as described above are mixed, and a DNA ligase, preferably T4 DNA ligase, is allowed to act on the mixture at a temperature of 4-16°C for 1 hour or more, preferably 6-24 hours, at an enzyme concentration of 1-100 units/ml to obtain recombinant DNA.

The vector autonomously replicable in *Escherichia coli* cells is preferably a plasmid vector autonomously replicable in the host cell, and examples thereof

include pUC19, pUC18, pBR322, pHSG299, pHSG399, pHSG398, RSF1010 and so forth.

Moreover, if a DNA fragment having an ability to make a plasmid autonomously replicable in coryneform bacteria (it can be prepared from, for example, pAM330 (refer to Japanese Patent Laid-open (Kokai) No. 58-67699), pHM1519 (refer to Japanese Patent Laid-open No. 58-77895), pCG1 (refer to Japanese Patent Laid-open No. 57-134500), pCG2 (refer to Japanese Patent Laid-open No. 58-35197), pCG4 (refer to Japanese Patent Laid-open No. 57-183799), pCG11 (refer to Japanese Patent Laid-open No. 57-183799) and so forth) is inserted into the aforementioned vectors, they can be used as a so-called shuttle vector autonomously replicable in both of *Escherichia coli* and coryneform bacteria.

Examples of such a shuttle vector include those mentioned below. There are also indicated microorganisms that harbor each vector, and accession numbers thereof at international depositories are shown in the parentheses, respectively.

pAJ655: *Escherichia coli* AJ11882 (FERM BP-136)

Corynebacterium glutamicum SR8201 (ATCC 39135)

pAJ1844: *Escherichia coli* AJ11883 (FERM BP-137)

Corynebacterium glutamicum SR8202 (ATCC39136)

pAJ611: *Escherichia coli* AJ11884 (FERM BP-138)

pAJ3148: *Corynebacterium glutamicum* SR8203 (ATCC 39137)

pAJ440: *Bacillus subtilis* AJ11901 (FERM BP-140)

By using the obtained recombinant DNA, for example, *Escherichia coli* K-12 strain is transformed to prepare a chromosomal DNA library. This transformation can be performed by the method of D.M. Morrison (*Methods in Enzymology*, 68, 326, 1979), the method comprising treatment of recipient cells with calcium chloride to increase their permeability for DNA (M. Mandel, and A. Higa, *J. Mol., Biol.*, 53, 159 (1970)) or the like.

Then, a mutant strain of a coryneform bacterium in which PBP does not function normally is transformed with the obtained chromosomal DNA library. As the method for transformation of coryneform bacteria, there is the aforementioned method utilizing a treatment of cells with calcium chloride or a method comprising allowing cells at a particular growth phase where they can take up DNA to take up it (reported for *Bacillus subtilis* by C.H. Duncan et al.). In addition to these, also employable is a method of making DNA-recipient cells into protoplasts or spheroplasts which can easily take up recombinant DNA, followed by allowing introduction of the recombinant DNA into the cells, which is known to be applicable to *Bacillus subtilis*, actinomycetes and yeasts (S. Chang, et al., *Molec. Gen. Genet.*, 168, 111 (1979); Bibb, et al., *Nature*, 274, 398 (1978); A. Hinnen, et al., *Proc. Natl. Sci. USA*, 75, 1929 (1978)). Other

than those, a method for transformation of coryneform bacteria is also disclosed in Japanese Patent Laid-open No. 2-207791).

5 A transformant strain introduced with a PBP gene can be obtained by plating the transformed mutant strain under a condition where a mutant strain (host) that is not transformed cannot grow, and selecting a strain that has formed a colony. A DNA fragment containing a PBP gene can be obtained from the obtained transformant by
10 isolating the recombinant DNA, for example, by the method of P. Guerry, et al. (*J. Bacteriol.*, 116, 1064 (1973)), the method of D.B. Clewell (*J. Bacteriol.*, 110, 667 (1972)) or the like. A coryneform bacterium transformed with recombinant DNA containing a PBP gene
15 can also possibly be obtained by hybridization using a gene coding for a known PBP of a microorganism, for example, PBP of *Escherichia coli*, or an oligonucleotide produced based on the nucleotide sequence thereof.

Besides the mutagenesis treatment, a coryneform
20 bacterium in which PBP does not function normally can be created by using a PBP gene obtained as described above. A PBP gene on chromosome can be disrupted by transforming a coryneform bacterium with DNA containing a PBP gene modified with internal deletion so as not to
25 produce PBP functioning normally (deletion type PBP gene), and allowing recombination between the deletion type PBP gene and the PBP gene on the chromosome. Such

gene destruction by homologous recombination has already been established, and there are methods utilizing a linear DNA, a plasmid that contains a temperature sensitive replication control region and so forth. In the present invention, the method utilizing a plasmid that contains a temperature sensitive replication control region is preferred.

A PBP gene on host chromosome can be replaced with the deletion type PBP gene as follows. That is, recombinant DNA is first prepared by inserting a temperature sensitive replication control region, mutant PBP gene and marker gene for resistance to a drug such as chloramphenicol, with which recombinant DNA a coryneform bacterium is transformed. Further, the resultant transformant strain is cultured at a temperature at which the temperature sensitive replication control region does not function, and then the transformant strain can be cultured in a medium containing the drug to obtain a transformant strain in which the recombinant DNA is incorporated into the chromosomal DNA.

In such a strain in which recombinant DNA is incorporated into chromosomal DNA, the mutant PBP gene is recombined with the PBP gene originally present on the chromosome, and the two fusion genes of the chromosomal PBP gene and the deletion type PBP gene are inserted into the chromosome so that the other portions

of the recombinant DNA (vector segment, temperature sensitive replication control region and drug resistance marker) should be present between the two fusion genes. Therefore, the transformant expresses PBP, because the
5 normal PBP gene is dominant in this state, and it can grow.

Then, in order to leave only the deletion type PBP gene on the chromosomal DNA, one copy of the PBP gene is eliminated together with the vector segment (including
10 the temperature sensitive replication control region and the drug resistance marker) from the chromosomal DNA by recombination of the two PBP genes. In that case, the normal PBP gene is left on the chromosomal DNA, and the deletion type PBP gene is excised from the chromosomal
15 DNA, or to the contrary, the deletion type PBP gene is left on the chromosomal DNA, and the normal PBP gene is excised from the chromosome DNA. In the both cases, the excised DNA may be retained in the cell as a plasmid when the cell is cultured at a temperature at which the
20 temperature sensitive replication control region can function. Subsequently, the cell is cultured at a temperature at which the temperature sensitive replication control region cannot function. In the culture, the cell cannot proliferate when the deletion
25 type PBP gene is left on the chromosomal DNA, since the plasmid containing the normal PBP gene is dropped from the cell. On the other hand, when the normal PBP gene

is left on the chromosomal DNA, the cell can proliferate. Thus, a strain in which the PBP gene on the chromosomal DNA is disrupted and the normal PBP gene is harbored on the plasmid can be obtained by selecting a strain that
5 can proliferate at a temperature at which the temperature sensitive replication control region functions, but cannot proliferate at a temperature at which the temperature sensitive replication control region does not function.

10 When the strain with the disrupted PBP gene obtained as described above is cultured at a temperature at which the temperature sensitive replication control region functions (for example, low temperature), it retains the PBP gene in the cell, and when it is
15 cultured at a temperature at which the temperature sensitive replication control region does not function (for example, high temperature), it loses the PBP gene. In the following description, a temperature at which a temperature sensitive plasmid cannot replicate is
20 referred to as a high temperature. However, it is not intended to exclude possibility that the temperature is a low temperature, and if a temperature sensitive replication control region is obtained which cannot replicate at a low temperature but can replicate at a
25 high temperature, it may also be used.

A strain which is made $recA^-$ after the PBP gene on chromosome DNA is disrupted and the normal PBP gene is

incorporated into a plasmid is preferably used as the microorganism used in the present invention, since in such a strain, incorporation of the PBP gene on the plasmid into the chromosome during culture at a low temperature is prevented and thus the drop of the gene is secured.

The temperature sensitive replication control region can be obtained by subjecting a plasmid autonomously replicable in a coryneform bacterium cell and having drug resistance to a mutagenesis treatment, transforming a coryneform bacterium with the plasmid and extracting a plasmid from a transformant that can grow at a low temperature but cannot grow at a high temperature in a medium containing the drug.

As the method for the mutagenesis of plasmid, there can be mentioned the method utilizing an in vitro treatment of plasmid with hydroxylamine (G.O. Humpherys, et al., *Molec. Gen. Genet.*, 145, 101-108 (1976) etc.).

The terms "low temperature" and "high temperature" herein used have relative concepts, and the border between the low temperature and the high temperature is not particularly limited. The "low temperature" means a temperature range wherein coryneform bacteria can at least proliferate when they are cultured. The "high temperature" means a temperature wherein coryneform bacteria themselves shall not die. The border of the low temperature and the high temperature can be

determined by cultivating a transformant harboring a temperature sensitive plasmid in a medium containing a drug at various temperatures to determine a lower limit temperature above which the transformant cannot grow.

5 Examples of the plasmid that has a temperature sensitive replication control region functioning in a coryneform bacterium cell include pHS4, pHS22 and pHS23. Plasmid pHSC4, which is obtained by ligating a DNA
10 fragment excised from pHS4 and containing a replication control region derived from a coryneform bacterium to a vector for *Escherichia coli*, pHSG398, can also be used for the present invention as a temperature sensitive plasmid. pHSC4 autonomously proliferates in coryneform bacteria and *Escherichia coli*, and it imparts
15 chloramphenicol resistance to a host. *Escherichia coli* AJ12571 harboring pHSC4 was deposited at the National Institute of Bioscience and Human-Technology, the Agency of Industrial Science and Technology, the Ministry of International Trade and Industry on October 11, 1990,
20 and received an accession number of FERM P-11763. Then, it was transferred to an international deposit under the provisions of the Budapest Treaty on August 26, 1991, and received an accession number of FERM BP-3524.

25 These temperature sensitive plasmids can autonomously proliferate at about 10-32°C in a coryneform bacterium cell, but they cannot autonomously proliferate at about 34°C or higher.

A DNA fragment that has a temperature sensitive replication control region can be obtained by, for example, digesting the aforementioned pHSC4 with *Bam*HI and *Kpn*I.

5 Construction of the aforementioned plasmids and nucleotide sequences of the regions containing a temperature sensitive replication control region thereof are disclosed in Japanese Patent Publication (Kokoku) No. 7-108228.

10 It is also known that, in *Escherichia coli*, some of a penicillin binding protein genes form a gene cluster, and *murE* gene and PBP3 gene (*ftsI*) are located closely to each other (F. Ishino, Nippon Nogeikagaku, Kaishi, vol.63, No.11, 1755-1764 (1989)). Therefore, a
15 PBP gene may be obtained together with the *murE* gene by transforming a *murE* temperature sensitive mutant as a host, which has been already obtained for coryneform bacteria, with a plasmid containing chromosomal DNA derived from a coryneform bacterium to obtain a
20 transformant strain that has come to be able to grow at a temperature at which the host cannot grow. The inventors of the present invention successfully obtained a PBP gene based on this concept as described in the examples mentioned below.

25 Further, since the nucleotide sequences of the PBP gene and flanking regions were elucidated by the present invention, the PBP gene can readily be obtained by

preparing primers based on the sequence and performing PCR (polymerase chain reaction; refer to T.J. White, et al., *Trends Genet.*, 5, 185 (1989)) utilizing coryneform bacterium chromosomal DNA as a template.

5 The nucleotide sequence containing the PBP gene obtained in the examples mentioned later is shown as SEQ ID NO: 1 in Sequence Listing. In this nucleotide sequence, there exist three opening reading frames (ORF) (nucleotide numbers 881-2623, 2790-4454 and 4467-5345).

10 The amino acid sequences encoded by the ORFs are shown as SEQ ID NOS: 2-4.

 When an existing protein database was searched for sequences exhibiting homology with these amino acid sequences, it was found that the amino acid sequence encoded by the first OFR showed homology of about 31% with the amino acid sequence encoded by the PBP3 gene (*ftsI*) of *Escherichia coli* on the amino acid level. The amino acid sequences encoded by the second and the third OFRs showed homology to the amino acid sequences encoded by the *murE* gene and the *murF* gene of *Escherichia coli*, respectively. These results suggested that the first OFR is the PBP gene corresponding to the *ftsI* of *Escherichia coli*.

25 The PBP gene of the present invention may code for substitution, deletion, insertion, addition or inversion of one or several amino acids, so long as the activity of the encoded protein for binding to penicillin is not

005000 " 905000

degraded. The number meant by the term "several" used herein may vary depending on locations in the three-dimensional structure of proteins and kinds of amino acid residues. This is due to the fact that there are
5 analogous amino acids among amino acids such as isoleucine and valine, and difference among such amino acids does not substantially affect the three-dimensional structure of proteins. Therefore, the encoded protein may be one having homology of 30-40% or
10 more, preferably 55-65% or more, with respect to the entire amino acid sequence constituting the protein, and having the activity for binding to penicillin.

Such DNA encoding a protein substantially the same as a penicillin binding protein as mentioned above can
15 be obtained by modifying the nucleotide sequence by, for example, the site-directed mutagenesis so that the amino acid residues of a specific site should include substitution, deletion, insertion, addition or inversion. Such modified DNA as mentioned above can also be
20 obtained by an already known mutagenesis treatment. Examples of the mutagenesis treatment include in vitro treatment of DNA coding for a penicillin binding protein with hydroxylamine etc., treatment of a microorganism having DNA coding for a penicillin binding protein, for
25 example, *Escherichia* bacteria, by ultraviolet irradiation or with a mutagenizing agent used for usual mutagenesis treatment such as N-methyl-N'-nitro-N-

nitrosoguanidine (NTG) or nitrous acid.

The substitution, deletion, insertion, addition or inversion of nucleotides described above also includes mutation (mutant or variant) that naturally occurs due to individual difference, difference in species or genera of the microorganism having a penicillin binding protein.

DNA coding for substantially the same protein as a penicillin binding protein can be obtained by expressing DNA having such a mutation as described above in an appropriate cell, and examining the penicillin binding activity of an expressed product. DNA coding for substantially the same protein as a penicillin binding protein can also be obtained by isolating DNA hybridizable with DNA having, for example, the nucleotide sequence of nucleotide numbers 881 to 2623 in SEQ ID NO: 1 in Sequence Listing under a stringent condition and coding for a protein having the penicillin binding activity from DNA coding for penicillin binding protein having mutation or from a cell harboring it. The "stringent condition" referred to herein is a condition under which a so-called specific hybrid is formed, and a non-specific hybrid is not formed. It is difficult to clearly express this condition by using numerical values. However, for example, the stringent condition includes a condition under which two of DNA having high homology, for example, two of DNA having

homology of not less than 50% are hybridized with each other, and two of DNA having homology lower than the above are not hybridized with each other. Alternatively, the stringent condition is exemplified by a condition under which two of DNA are hybridized with each other at a salt concentration corresponding to an ordinary condition of washing in Southern hybridization, i.e., 60°C, 1 x SSC, 0.1% SDS, preferably 0.1 x SSC, 0.1% SDS.

The genes hybridizable under the condition as described above includes those having a stop codon generated in the gene, and those having no activity due to mutation of the active center. However, such mutant genes can be easily removed by ligating the genes with a commercially available activity expression vector, and measuring the penicillin binding activity.

<3> Production of L-glutamic acid

L-Glutamic acid can be produced by cultivating such a coryneform bacterium as described above in which PBP does not function normally and which has L-glutamic acid producing ability in a liquid medium to produce and accumulate L-glutamic acid in the medium, and collecting the L-glutamic acid. According to the method of the present invention, L-glutamic acid can be produced in a medium containing a significant amount of biotin such as molasses without adding a biotin activity inhibitor.

When the coryneform bacterium used is a bacterium

of which PBP normally functions at the first temperature and does not normally function at the second temperature, the bacterium is cultured at the first temperature to allow it to proliferate, and then cultured with shifting
5 the temperature to the second temperature to produce L-glutamic acid.

Specifically, the temperature shifting can be attained by, for example, performing seed culture at a low temperature and performing culture in a main medium
10 (main culture) at a high temperature. The temperature may also be shifted during preculture or main culture. The step of cell proliferation and the step of drop of plasmid are not clearly distinguished, and the step of drop of plasmid is accompanied with proliferation of
15 cells.

As for the timing of the temperature shift, the period for the culture at a low temperature can readily be decided by carrying out preliminarily experiments with various periods of culture until the temperature
20 shift. In general, the culture can be continued until a desired cell density is attained in the logarithmic growth phase, and then the temperature can be shifted to a level at which the plasmid cannot replicate.

The medium used for the culture is not
25 particularly limited, and there can be used a usual medium containing a carbon source, nitrogen source, and inorganic ions as well as organic trace nutrients as

required. In the present invention, in particular, a medium containing a significant amount of biotin may be used.

As the carbon source, there can be used
5 saccharides such as glucose, lactose, galactose, fructose and hydrolysate of starch, alcohols such as ethanol and inositol, organic acids such as acetic acid, fumaric acid, citric acid and succinic acid and so forth.

As the nitrogen source, inorganic ammonium salts
10 such as ammonium sulfate, ammonium chloride and ammonium phosphate, organic nitrogen such as soybean hydrolysate, ammonia gas, aqueous ammonia and so forth can be used.

As the inorganic ions or sources thereof, a small
amount of potassium phosphate, magnesium sulfate, iron
15 ions, manganese ions and so forth may be added. As a trace amount organic nutrient, it is desirable to add a suitable amount of required substances such as vitamin B₁ and yeast extract and so forth as required.

The culture is preferably performed for 16 to 72
20 hours under an aerobic condition, and the culture temperature is controlled to be 20 to 45°C, and pH to be 5-8.5 during the culture. For adjusting pH, inorganic or organic acidic or alkaline substances, ammonia gas and so forth can be used.

25 Collection of L-glutamic acid from the culture can usually be carried out by using a combination of known techniques such as techniques using ion exchange resins,

precipitation methods and so forth.

Brief Description of the Drawing

5 Fig. 1 is a graph showing inhibition by mecillinam for binding of PBP3 and penicillin G. The arrow indicates the minimum inhibitory concentration.

Best Mode for Carrying out the Invention

10 Hereafter, examples of the present invention will be explained.

Example 1: Detection of PBP of coryneform bacteria

15 Detection of PBP of coryneform bacteria was performed based on the aforementioned method of Spratt, et al., and specifically as follows.

<1> Preparation of membrane fraction

20 PBP is considered to be a membrane protein. A membrane fraction of a coryneform bacterium was prepared as follows. A wild strain of coryneform bacteria, *Brevibacterium lactofermentum* ATCC 13869 strain, was inoculated to 20 ml of A medium (containing 10 g of polypeptone, 5 g of yeast extract, 5 g of NaCl and 5 g
25 of glucose in 1 L of water), cultured at 30°C with shaking, and harvested when the absorption at 660 nm reached about 1.0. The cells were washed in 50 mM

sodium phosphate buffer, pH 7.0. Then, the buffer was added with glass beads and sonicated to disrupt the cells. After the disruption debris was removed by centrifugation, the buffer was subjected to
5 ultracentrifugation at 100,000 x g for 30 minutes to collect a membrane fraction. The obtained fraction was washed with the same buffer, and the fraction finally suspended in 500 μ l of the same buffer was used as the membrane fraction. Protein concentration of this
10 membrane fraction was determined by using a protein quantification kit (produced by PIERCE, Micro BCA Protein assay kit), and found to be 4 mg/ml.

<2> Penicillin binding reaction

15 A volume of 30 μ l of the prepared membrane fraction was added with 3 μ l of 14 C-penicillin G (produced by Amersham) and allowed to react at 30°C for 10 minutes. Then, it was added with 2 μ l of 15% sarcosyl (sodium N-lauroylsarcosine) and 45 mg/ml of
20 penicillin G, and left for 20 minutes at room temperature. Then, the fraction was centrifuged at 13,000 rpm for 30 minutes at 20°C to obtain a soluble fraction. A sample of this fraction was subjected to
25 SDS-PAGE using gel containing 10% of polyacrylamide, and the gel was fixed, dried and analyzed with an image analyzer BAS2000 produced by Fuji Photo Film Co., Ltd. As a result, three bands were detected at 110 kDa, 100

kDa and 60 kDa, and designated as PBP1, PBP2 and PBP3, respectively.

<3> Analysis using PBP binding inhibitor

5 Affinity between mecillinam, which is a derivative
of penicillin G, and PBP was investigated. The affinity
between the derivative and PBP was investigated by
adding mecillinam at various concentrations before the
aforementioned penicillin binding reaction, and
10 measuring degree of inhibition of the binding with
isotope (^{14}C) labeled penicillin G. As a result, only
PBP3 was inhibited for binding with the labeled
penicillin G by the addition of mecillinam. That is, it
was clarified that mecillinam should selectively bind to
15 PBP3 (Fig. 1).

Example 2: Glutamic acid production by coryneform
bacterium induced by addition of mecillinam

20 The *Brevibacterium lactofermentum* ATCC 13869
strain was inoculated to the aforementioned A medium,
cultured at 30°C for 2 hours with shaking, then added
with $0.01\ \mu\text{M}$ to $100\ \mu\text{M}$ of mecillinam, and further
cultured for 8 hours with shaking. Subsequently,
glutamic acid concentration in the medium was measured
25 by using Biotech Analyzer AS210 (produced by Asahi
Chemical Industry Co., Ltd.) (Table 1).

Table 1

Concentration of added mecillinam (μ M)	Concentration of L- glutamic acid (mg/L)
0	0
0.1	0
1.0	0
10	0
100	575

Since it was only PBP3 that bound to mecillinam under the condition where L-glutamic acid production was induced by addition of mecillinam, it was demonstrated that the glutamic acid production induced by the addition of penicillin or mecillinam was caused at least by inhibition of the function of PBP3.

Example 3: Cloning of PBP gene of *Brevibacterium lactofermentum* ATCC 13869

(1) Preparation of chromosomal DNA of *Brevibacterium lactofermentum* ATCC 13869

The *Brevibacterium lactofermentum* ATCC 13869 strain was cultured overnight in 10 ml of L medium (1% of polypeptone, 0.5% of yeast extract, 0.5 g of NaCl, 0.1% of glucose, pH 7.2), and harvested. The cells were washed with 50 mM Tris-HCl, 50 mM EDTA buffer (pH 8.0), and suspended in 800 μ l of the same buffer.

To the aforementioned cell suspension, 40 μ l of a 50 ml/ml lysozyme solution and 20 μ l of a 10 mg/ml ribonuclease solution were added, and the mixture was incubated at 37°C for 1 hour. The mixture was added

with 20 μ l of a 20% SDS solution, and incubated at 70°C for 1 hour. Then, the mixture was added with 24 μ l of a 20 mg/ml proteinase K solution, incubated at 50°C for 1 hour, further added with 24 μ l of the proteinase K solution, and incubated for 1 hour.

The cell lysate obtained as described above was added with an equal amount of phenol and stirred. The lysate was left at 4°C overnight, and then centrifuged to collect an aqueous layer. The aqueous layer was extracted with phenol/chloroform for 2 hours, and with chloroform/isoamyl alcohol for 30 minutes. The extraction was carried out by leaving the lysate after stirring for a predetermined period of time and centrifuging it to collect an aqueous layer. DNA was collected from the obtained extract by ethanol precipitation. The precipitation of DNA was dissolved in 300 μ l of TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0).

(2) Preparation of chromosomal DNA library of *Brevibacterium lactofermentum* ATCC 13869

The chromosomal DNA of the *Brevibacterium lactofermentum* ATCC 13869 obtained as described above and a high copy number vector pHSG398 of *Escherichia coli* (Takara Shuzo) were digested by with a restriction enzyme HindIII (Takara Shuzo). These two of DNA were mixed in suitable amounts and ligated by using Takara

DNA Ligation Kit ver. 2 (Takara Shuzo) to construct a chromosomal DNA library of *Brevibacterium lactofermentum* ATCC 13869.

5 (3) Selection of PBP gene clone

10 A *murE* mutant strain TLK11 of *Escherichia coli* (*murE* temperature sensitive mutation, J. Bacteriol., 1972, 110:41-46) was transformed with the chromosomal DNA library of the *Brevibacterium lactofermentum* ATCC 13869 obtained as described above, and cultured at 42°C overnight on L agar medium (L medium containing 1.5% of agar) containing 20 µg/ml of chloramphenicol.

15 An emerged colony was inoculated to L liquid medium, and cultured, and plasmid was collected from the obtained cells. As a result, a *Hind*III fragment of about 5.3 kb was cloned in the plasmid. This plasmid was designated as pHS GH-H.

20 (4) Determination of nucleotide sequence of cloned DNA fragment

The aforementioned cloned fragment was subjected to the dideoxy reaction using Thermo Sequenase fluorescent labelled primer cycle sequencing kit with 7-deaza-dGTP (Amersham Pharmacia Biotech) and determined for the nucleotide sequence by using a DNA sequencer DSQ-1000L (Shimadzu). The determined nucleotide sequence is shown as SEQ ID NO: 1.

Example 4: Construction of PBP gene-disrupted strain of
Brevibacterium lactofermentum

5 A *Brevibacterium lactofermentum* strain with
disrupted PBP gene on the chromosome was created by the
homologous recombination using the temperature sensitive
plasmid disclosed in Japanese Patent Laid-open No. 5-
7491.

10 PCR was performed by using pHSGH-H as a template
and oligonucleotides having the nucleotide sequences
shown as SEQ ID NOS: 5 and 6 as primers to amplify a PBP
gene fragment. The primer shown as SEQ ID NO: 5
contained a sequence corresponding to nucleotide numbers
31-50 of the nucleotide sequence shown as SEQ ID NO: 1,
15 and the primer shown as SEQ ID NO: 6 contained a
sequence corresponding to nucleotide numbers 2991-3014
of the nucleotide sequence shown as SEQ ID NO: 1, and
each had an EcoRI recognition sequence in the 5' end
sequence. The PCR reaction was carried out by using a
20 commercially available PCR apparatus (DNA Thermal Cycler
Model PJ2000 produced by Takara Shuzo etc.), and TaqDNA
Polymerase (Takara Shuzo) according to the
manufacturer's protocol.

25 The obtained amplified fragment was treated with
EcoRI, and inserted into the EcoRI site of pHSG299
(produced by Takara Shuzo) to produce pHSGE. Separately,
the temperature sensitive plasmid for coryneform

bacteria, pHSC4, was digested with BamHI and KpnI to obtain a gene fragment containing a replication control region, and the obtained fragment was blunt-ended by using Blunting kit produced by Takara Shuzo, and
5 inserted into the XbaI site of pHSGE using a XbaI linker (produced by Takara Shuzo) to produce pHSGX. Then, pHSGX was digested with BamHI and KpnI, blunt-ended by using Blunting kit produced by Takara Shuzo and allowed to cause self-ligation by using Takara DNA Ligation Kit
10 ver. 2 (Takara Shuzo). The obtained plasmid pHSGX Δ BK had an internal deletion of the PBP gene.

By using the plasmid pHSGX Δ BK for PBP gene substitution obtained as described above, gene
substitution between a deletion type PBP gene and a PBP
15 gene on chromosomal DNA of *Brevibacterium lactofermentum* was performed by the double recombination technique. Specifically, it was attained as follows. The *Brevibacterium lactofermentum* ATCC 13869 was transformed with pHSGX Δ BK by the electric pulse method (see Japanese
20 Patent Laid-open No. 2-207791). The transformant was cultured at 25°C for 6 hours in M-CM2G liquid medium with shaking and inoculated on M-CM2G medium containing 25 μ g/ml of kanamycin. A strain that formed a colony at 34°C was obtained.

25 In the obtained strain, the deletion type PBP gene was recombined with the PBP gene originally present on the chromosome, and the two fusion genes of the

chromosomal PBP gene and the deletion type PBP gene are inserted into the chromosome so that the other portions of the recombinant DNA (vector segment, temperature sensitive replication control region and drug resistance marker) should be present between the two fusion genes. Therefore, the transformant strain could grow at a high temperature because the normal PBP gene was dominant in this state.

Then, the transformant strain was cultured at 25°C, and a strain in which the PBP gene on the chromosome was replaced with the deletion type gene was selected from the strains that could grow at 25°C but could not grow at 34°C, and designated as $\Delta P3/p3$ strain. In the $\Delta P3/p3$ strain, the deletion type PBP gene was left on the chromosomal DNA, and a plasmid containing a normal PBP gene was present in the cell. It was confirmed if the PBP gene on the chromosome was replaced with the deletion type by determining the nucleotide sequence of the ligation region left behind the deleted region.

Industrial Applicability

According to the present invention, a gene coding for a penicillin binding protein (PBP gene) of a coryneform bacterium is provided. By using a coryneform bacterium of which PBP gene on the chromosome was disrupted with the gene, L-glutamic acid can be produced

THE **NEW** **YORK** **PUBLIC** **LIBRARY** **ASTOR LENOX TILDEN FOUNDATION**

What is claimed is:

1. A method for producing L-glutamic acid, comprising the steps of cultivating a coryneform bacterium in a liquid medium to produce and accumulate
5 L-glutamic acid in the medium, and collecting the L-glutamic acid, wherein penicillin binding protein (PBP) does not normally function in said bacterium and said bacterium has the ability to produce L-glutamic acid.
- 10 2. The method according to claim 1, wherein the coryneform bacterium is a bacterium in which penicillin binding protein functions normally at the first temperature and does not function normally at the second temperature,
15 comprising the steps of cultivating the bacterium at the first temperature to proliferate the bacterium, and cultivating the bacterium at the second temperature to produce L-glutamic acid.
- 20 3. The method according to claim 2, wherein the coryneform bacterium is a bacterium which harbors a plasmid comprising a gene coding for a penicillin binding protein (PBP gene) and a temperature sensitive replication control region, and in which the PBP gene on
25 chromosome does not function, and the plasmid can replicate at the first temperature, and cannot replicate at the second temperature.

4. The method according to claim 2, wherein the penicillin binding protein produced by the coryneform bacterium has a temperature sensitive mutation.

5

5. The method according to any one of claims 1-4, wherein the penicillin binding protein shows a molecular weight of about 60,000 in SDS-polyacrylamide gel electrophoresis, when the penicillin binding protein binds to penicillin G.

10

6. The method according to any one of claims 1-4, wherein the penicillin binding protein has the amino acid sequence shown in SEQ ID NO: 2 in Sequence .

15

7. The method according to claim 3, wherein the PBP gene has a nucleotide sequence comprising at least the sequence of the nucleotide numbers 881 to 2623 of SEQ ID NO: 1 in Sequence Listing.

20

8. DNA which codes for a protein defined in the following (A) or (B):

(A) a protein which has the amino acid sequence of SEQ ID NO: 2 in Sequence Listing;

25

(B) a protein which has an amino acid sequence of SEQ ID NO: 2 in Sequence Listing including substitution, deletion, insertion, addition or inversion of one or

several amino acids, and an activity for binding to penicillin.

5 9. The DNA according to claim 7, which is DNA defined in the following (a) or (b):

(a) DNA which comprises at least the nucleotide sequence of the nucleotide numbers 881 to 2623 of SEQ ID NO: 1 in Sequence Listing;

10 (b) DNA which is hybridizable with a nucleotide sequence comprising at least the sequence of the nucleotide numbers 881 to 2623 of SEQ ID NO: 1 in Sequence Listing under a stringent condition, and codes for a protein having an activity for binding to penicillin.

15

Abstract

L-glutamic acid is produced by cultivating a coryneform bacterium having L-glutamic acid producing ability in which the PBP gene on the chromosomal DNA is disrupted and the normal PBP gene is harbored on the plasmid comprising a temperature sensitive replication control region in a liquid medium at a temperature at which the temperature sensitive replication control region does not function, and then cultivating the bacterium at a temperature at which the temperature sensitive replication control region functions normally to produce L-glutamic acid.

1 / 1




Fig. 1

Declaration, Power Of Attorney and Petition

Page 1 of 3

WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first, and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A GENE CODING FOR PENICILLIN BINDING PROTEIN AND A METHOD FOR PRODUCING
L-GLUTAMIC ACID

the specification of which

☒ is attached hereto.

☐ was filed on _____ as

Application Serial No. _____

and amended on _____.

☒ was filed as PCT international application

Number PCT/JP 99/01084

on March 5, 1999,

and was amended under PCT Article 19

on _____ (if applicable).

We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations.

We (I) hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s)

Application No.	Country	Day/Month/Year	Priority Claimed
10-55608	Japan	06/03/1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No
_____	_____	_____	<input type="checkbox"/> Yes <input type="checkbox"/> No

We (I) hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

(Application Number)

(Filing Date)

We (I) hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Serial No.

Filing Date

Status (pending, patented,
abandoned)

And we (I) hereby appoint: Norman F. Oblon, Registration Number 24,618; Marvin J. Spivak, Registration Number 24,913; C. Irvin McClelland, Registration Number 21,124; Gregory J. Maier, Registration Number 25,599; Arthur I. Neustadt, Registration Number 24,854; Richard D. Kelly, Registration Number 27,757; James D. Hamilton, Registration Number 28,421; Eckhard H. Kuesters, Registration Number 28,870; Robert T. Pous, Registration Number 29,099; Charles L. Gholz, Registration Number 26,395; Vincent J. Sunderdick, Registration Number 29,004; William E. Beaumont, Registration Number 30,996; Steven B. Kelber, Registration Number 30,073; Robert F. Gnuse, Registration Number 27,295; Jean-Paul Lavalleye, Registration Number 31,451; Timothy R. Schwartz, Registration Number 32,171; Stephen G. Baxter, Registration Number 32,884; Martin M. Zoltick, Registration Number 35,745; Robert W. Hahl, Registration Number 33,893; Richard L. Treanor, Registration Number 36,379; Steven P. Weihrouch, Registration Number 32,829; John T. Goolkasian, Registration Number 26,142; Marc R. Labgold, Registration Number 34,651; William J. Healey, Registration Number 36,160; and Richard L. Chinn, Registration Number 34,305; our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this application be sent to the firm of OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., whose Post Office Address is: Fourth Floor, 1755 Jefferson Davis Highway, Arlington, Virginia 22202.

We (I) declare that all statements made herein of our (my) own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Customer # 22850

Masaaki WACHI

NAME OF FIRST SOLE INVENTOR

Residence: Machida-shi, Tokyo, Japan

JP

Masaaki Wachi

Signature of Inventor

Citizen of: Japan

Post Office Address: 1-4-1-13-202,

Minamitsukushino, Machida-shi,

Tokyo, 194-0002 Japan

August 18, 2000

Date

2-00

Kazuo NAGAI

NAME OF SECOND JOINT INVENTOR

Residence: Toshima-ku, Tokyo, Japan

JP

Signature of Inventor

Citizen of: Japan

Post Office Address: 3-42-17,

Ikebukuro, Toshima-ku, Tokyo,

171-0014 Japan

August 18, 2000

Date

NAME OF THIRD JOINT INVENTOR

Signature of Inventor

Date

NAME OF FOURTH JOINT INVENTOR

Signature of Inventor

Date

NAME OF FIFTH JOINT INVENTOR

Signature of Inventor

Date

SEQUENCE LISTING

<110> WACHI, Masaaki
NAGAI, Kazuo

<120> A Gene Coding for Penicillin Binding Protein
and a Method for Producing L-Glutamic Acid

<130> OP843-PCT

<141> 1999-03-05

<150> JP 10-55608

<151> 1998-03-06

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 5347

<212> DNA

<213> Brevibacterium lactofermentum

<220>

<221> CDS

<222> (881)..(2623)

<220>

<221> CDS

<222> (2790)..(4454)

<220>

<221> CDS

<222> (4467)..(5345)

<400> 1

aagcttcggg gaggggcgcg tcgataagca cgcaacctcg tcgtgacatg gcgccggaaa 60
ggaacaacc cgggccctgg tgaacctgg cgtgcagcaa cgcgtaattg atgcagcaca 120
agctgggctc tcagcaggtt atgtcgggtc gtggtcgccg cgttgaggca aaacgtgctg 180
atcctaaggt gatccagctg tctgtgctgg tggttatcct gctgtgcgtt ggtgttgccg 240
cgaccatggg tctgtccgga acgtctacac agcagacttt ccagttgcag gaacttcagg 300
caactgaaac ggatttgagc aatcgattg agtctctcaa ccgagatgtg gaagatgctc 360
gtcagcagc aaccttgga cgaatgcta cggagatggg cttggtatcc ccagtgaac 420
ctggcgtgct cgcagtgcag gaaaacggtg atgttgtgga ggagcgcgaa caaatccaga 480
gacacgcct atagttgaca tcaatggaca acagaccga ccaaacggg catcaagcaa 540
ccctgacgag actaacgat actgaaaacc tccaggcgat tccacaagaa gcagcagctc 600
cgccgtatca gaccaacact gttccttatg ctgcaaccac cggacaagca ggtggcgcag 660

ggcagtgact	ttccccagca	atggcgagaag	tgggggcgag	cgtgcgggac	gtgaagatac	720
gtcccgccgt	tggcggtatc	aggacgaaag	cagaagagcc	gctagagagc	gcgaacttac	780
gcgacgcagc	ggtaaagcta	aaggcgtaaa	ccaagaagaa	ggagtgcact	accggcctaa	840
atcttcaacc	cagggcggcg	cacgcaagcg	acgtgtgaac	atg Met	gtt Val	acc Thr
				1	cgt Arg	atc Ile
						5
gca	ttg	gtc	atc	gct	ggc	gta
Ala	Leu	Val	Ile	Ala	Gly	Val
				10		Leu
						15
						20
gtt	gtc	tgg	gga	cca	gaa	ctg
Val	Val	Trp	Gly	Pro	Glu	Leu
			25			30
						35
cgc	gtg	tac	gta	gat	cct	gca
Arg	Val	Tyr	Val	Asp	Pro	Ala
		40				45
						50
gga	aac	cag	atg	gcg	tac	acg
Gly	Asn	Gln	Met	Ala	Tyr	Thr
	55				60	
						65
cgc	aac	atc	atg	cgt	gag	gaa
Pro	Asn	Ile	Met	Arg	Glu	Glu
	70				75	
						80
cgt	ttg	gcg	gct	gaa	gaa	acc
Arg	Leu	Ala	Ala	Glu	Glu	Thr
			90			95
						100
acc	atc	gaa	gaa	ggc	aac	gcg
Thr	Ile	Glu	Glu	Gly	Asn	Ala
		105				110
						115
gaa	acc	att	ctg	tcc	gac	aag
Glu	Thr	Ile	Leu	Ser	Asp	Lys
		120				125
						130
gat	cgg	atc	cct	gag	atc	atc
Asp	Arg	Ile	Pro	Glu	Ile	Ile
	135				140	
						145
att	tcc	tct	gag	gag	atc	ctg
Ile	Ser	Ser	Glu	Glu	Ile	Leu
	150				155	
						160
gag	gtg	ctc	gtc	cgc	aat	ggt
Glu	Val	Leu	Val	Arg	Asn	Val
			170			175
						180
gat	gag	atg	ccc	agc	gtc	gca
Asp	Glu	Met	Pro	Ser	Val	Ala
			185			190
						195

cca Pro	aac Asn	ggc Gly 200	gcg Ala	att Ile	ggg Gly	gaa Glu	aac Asn 205	atc Ile	atc Ile	ggg Gly	cga Arg	atc Ile 210	agc Ser	atg Met	gac Asp	1519
ggc Gly	gaa Glu 215	ggc Gly	cag Gln	ttc Phe	ggc Gly	ttt Phe 220	gag Glu	gct Ala	tcc Ser	aac Asn 225	gat Asp	tcc Ser	ctg Leu	ttg Leu	gca Ala	1567
gga Gly 230	aac Asn	aac Asn	ggg Gly	cgc Arg	tca Ser 235	acc Thr	cag Gln	gac Asp	atg Met	tcc Ser 240	att Ile	ttg Leu	gga Gly	caa Gln	gca Ala 245	1615
atc Ile	ccg Pro	ggc Gly	acg Thr	ttg Leu 250	agg Arg	gat Asp	caa Gln	att Ile	cca Pro 255	gcc Ala	att Ile	gat Asp	ggg Gly	gcc Ala 260	agc Ser	1663
gtt Val	gaa Glu	ctc Leu	acc Thr 265	gtt Val	gat Asp	ctg Leu	gat Asp	ctg Leu 270	caa Gln	acc Thr	tat Tyr	gtg Val	cag Gln 275	cag Gln	gca Ala	1711
ttg Leu	gag Glu	cag Gln 280	gcg Ala	aaa Lys	gct Ala	aac Asn	tcc Ser 285	ggg Gly	gca Ala	gaa Glu	aac Asn 290	gcc Ala	tcc Ser	gct Ala	gtg Val	1759
gtt Val	ctt Leu 295	gat Asp	gcc Ala	gag Glu	acc Thr 300	gct Ala	gag Glu	gtt Val	ttg Leu	gcg Ala 305	atg Met 305	gca Ala	aac Asn	acc Thr	gat Asp	1807
acc Thr 310	atc Ile	aac Asn	ccc Pro	aac Asn	gaa Glu 315	gac Asp	acg Thr	gga Gly	aag Lys	cag Gln 320	att Ile	gag Glu	cag Gln	ggc Gly 325	aag Lys 325	1855
agc Ser	ttt Phe	gac Asp	aat Asn	cct Pro 330	tct Ser	gtc Val	acc Thr	cac His	ccc Pro 335	ttc Phe	gag Glu	cct Pro	ggg Gly 340	tct Ser	gta Val	1903
gcc Ala	aag Lys	gtg Val	att Ile 345	act Thr	gca Ala	gca Ala	ggc Gly	gta Val 350	att Ile	caa Gln	gac Asp	ggc Gly 355	ttg Leu	act Thr	act Thr	1951
cca Pro	gat Asp	gaa Glu 360	gtg Val	ttg Leu	cag Gln	gta Val	ccg Pro 365	ggc Gly	agt Ser	att Ile	gaa Glu	atg Met 370	gcc Ala	ggg Gly	gtt Val	1999
tct Ser	gtc Val 375	ggg Gly	gat Asp	gcg Ala	tgg Trp 380	gac Asp	cac His	ggg Gly	gtc Val	gtt Val 385	ccc Pro	tat Tyr	acc Thr	act Thr	gca Ala	2047
gga Gly 390	att Ile	ttt Phe	ggg Gly	aag Lys	tcc Ser 395	tcg Ser	aat Asn	gta Val	ggc Gly	act Thr 400	ctg Leu	atg Met	ctt Leu	gcg Ala	cac His 405	2095
ggg Gly	ctt Leu	ggg Gly	gaa Glu	gat Asp 410	aaa Lys	ttt Phe	gct Ala	gat Asp	tac Tyr 415	ctg Leu	gaa Glu	cga Arg	ttc Phe	ggg Gly 420	gtg Val	2143
gga	cag	tca	acg	ggg	att	gag	ctt	ccg	agc	gaa	tcc	caa	ggc	ctg	ctg	2191

Gly 425	Gln	Ser	Thr 425	Gly	Ile	Glu	Leu	Pro 430	Ser	Glu	Ser	Gln	Gly 435	Leu	Leu	
ccc Pro	gca Ala	cgt Arg 440	gag Glu	cag Gln	tgg Trp	tct Ser	ggc Gly 445	ggg Gly	act Thr	ttt Phe	gct Ala	aac Asn 450	ctg Leu	ccc Pro	atc Ile	2239
ggg Gly 455	cag Gln	ggg Gly	atg Met	tgg Ser	atc Ile	acc Thr	acg Thr	ttg Leu	caa Gln	atg Met	gct Ala 465	gga Gly	atc Ile	tac Tyr	caa Gln	2287
gcc Ala 470	ttg Leu	gcc Ala	aac Asn	gat Asp	ggg Gly 475	gaa Glu	cgc Arg	att Ile	gaa Glu	cgc Pro 480	cgg Arg	atc Ile	atc Ile	aag Lys	agc Ser 485	2335
gtg Val	act Thr	gat Asp	tct Ser	gac Asp 490	gga Gly	aca Thr	gtc Val	cta Leu	gag Glu 495	cag Gln	cgc Pro	gaa Glu	ccc Pro	gat Asp 500	aaa Lys	2383
atc Ile	cag Gln	gtt Val	gtc Val 505	agc Ser	gct Ala	gaa Glu	gct Ala	gcc Ala 510	cgc Arg	acc Thr	acg Thr	gtg Val 515	gat Asp	atg Met	ttt Phe	2431
agg Arg	tct Ser	gtc Val 520	acc Thr	cag Gln	gtt Val	gat Asp	cca Pro 525	ctt Leu	gga Gly	gtg Val	cac His	aag Lys 530	gta Val	cgc Pro	ctc Leu	2479
cag Gln	acg Thr	cct Pro	cca Pro	ttg Leu	agg Arg	gtt Val 540	atc Ile	aaa Lys	tct Ser	cag Gln	gta Val 545	aga Arg	cag Gln	gta Val	cgc Arg	2527
cgc Arg 550	aaa Lys	aag Lys	ttg Leu	acc Thr	cca Pro 555	aca Thr	cgc Arg	cgt Arg	act Thr 560	cta Leu	act Thr	cgc Arg	aat Asn	act Thr 565		2575
gga Gly	tta Leu	cct Pro	tct Ser	cgc Arg 570	gta Val	ttg Leu	cac His	cgc Pro	ctg Leu 575	atg Met	atc Ile	ctc Leu	gat Asp	ttg Leu 580	ttg Leu	2623
tagccatcat	gcttgatgag	ccagaacgcg	gagtcacgcg	tggtggcggc	caaaccgcag											2683
cacctttgtt	caaagacatc	gccacctggt	tgctcaaccg	cgacaacatc	ccactgtctg											2743
cagccaccga	accgatcatc	cttcaagctc	aataactcaa	acagaa	gtg Val 1	tct Ser	ttt Phe									2798
gta Val	gaa Glu	ttt Phe	cat His	aat Asn	ctg Leu	aac Asn	ttt Phe	tgt Cys	ttg Leu	aac Asn	tct Ser	ttt Phe	cgc Arg	cat His	cac His	2846
cca Pro 20	ogt Arg	gcc Ala	gcg Ala	tcc Ser	gaa Glu 25	tta Leu	tta Leu	aca Thr	cct Pro	aga Arg 30	aac Asn	ctg Leu	tgg Trp	agg Arg	aga Arg 35	2894
gaa Glu	aac Asn	cat His	ggc Gly	aac Asn 40	cac His	gtt Val	gct Ala	gga Gly	cct Pro	cac His	caa Gln	act Thr	tat Tyr	cga Arg 50	tggt Trp	2942

cat cct caa ggg ctc tgc cag ggc gtt ccc gct cac gca gta ggg gaa His Pro Gln Gly Leu Cys Gln Gly Val Pro Ala His Ala Val Gly Glu 55 60 65	2990
caa gca atc gcg gct att ggt ctt gac tcc tcc agc ttg cct acc tcg Gln Ala Ile Ala Ala Ile Gly Leu Asp Ser Ser Ser Leu Pro Thr Ser 70 75 80	3038
gac gct att ttt gct gca gtt cca gga acc cgc act cac ggc gca cag Asp Ala Ile Phe Ala Ala Val Pro Gly Thr Arg Thr His Gly Ala Gln 85 90 95	3086
ttt gca ggt acg gat aac gct gcg aaa gct gtg gcc att ttg act gac Phe Ala Gly Thr Asp Asn Ala Ala Lys Ala Val Ala Ile Leu Thr Asp 100 105 110 115	3134
gca gct gga ctt gag gtg ctc aac gaa gca gga gag acc cgc cca atc Ala Ala Gly Leu Glu Val Leu Asn Glu Ala Gly Glu Thr Arg Pro Ile 120 125 130	3182
atc gtt gtt gat gat gtc gcg gca gta ctt ggc gca gca tca tca agc Ile Val Val Asp Asp Val Arg Ala Val Leu Gly Ala Ala Ser Ser Ser 135 140 145	3230
att tat ggc gat cct tca aaa gat ttc acg ctc att gga gtc act gga Ile Tyr Gly Asp Pro Ser Lys Asp Phe Thr Leu Ile Gly Val Thr Gly 150 155 160	3278
acc tca ggt aaa acc acc acc agc tac ctc ttg gaa aaa gga ctc atg Thr Ser Gly Lys Thr Thr Thr Ser Tyr Leu Leu Glu Lys Gly Leu Met 165 170 175	3326
gag gca ggc cac aaa gtt ggt ttg atc ggc acc aca ggt aca cgt ata Glu Ala Gly His Lys Val Gly Leu Ile Gly Thr Thr Gly Thr Arg Ile 180 185 190 195	3374
gat ggg gaa gaa gta ccc acg aag ctc acc act cca gaa gcg ccg act Asp Gly Glu Glu Val Pro Thr Lys Leu Thr Thr Pro Glu Ala Pro Thr 200 205 210	3422
ctg cag gca ttg ttt gct cga atg cgc gat cac ggt gtc acc cac gtg Leu Gln Ala Leu Phe Ala Arg Met Arg Asp His Gly Val Thr His Val 215 220 225	3470
gtg atg gaa gta tcc agc cat gca ttg tca ttg ggc agg gtt gcg ggt Val Met Glu Val Ser Ser His Ala Leu Ser Leu Gly Arg Val Ala Gly 230 235 240	3518
tcc cac ttt gat gta gct gcg ttt acc aac ctg tcg cag gat cac ctt Ser His Phe Asp Val Ala Ala Phe Thr Asn Leu Ser Gln Asp His Leu 245 250 255	3566
gat ttc cac ccc acc atg gat gat tac ttt gac gcg aag gca ttg ttc Asp Phe His Pro Thr Met Asp Asp Tyr Phe Asp Ala Lys Ala Leu Phe 260 265 270 275	3614
ttc gcg gca gat tct cca ctt gtg gct gac aaa cag gtc gtg tgc gtg Phe Arg Ala Asp Ser Pro Leu Val Ala Asp Lys Gln Val Val Cys Val 280 285 290 295	3662

280										285				290				
gat	gat	tct	tgg	ggt	cag	cgc	atg	gcc	agc	gtg	gca	gcg	gat	gtg	caa	3710		
Asp	Asp	Ser	Trp	Gly	Gln	Arg	Met	Ala	Ser	Val	Ala	Ala	Asp	Val	Gln			
			295				300						305					
aca	gta	tcc	acc	ctt	ggg	caa	gaa	gca	gac	ttc	agc	gct	aca	gat	atc	3758		
Thr	Val	Ser	Thr	Leu	Gly	Gln	Glu	Ala	Asp	Phe	Ser	Ala	Thr	Asp	Ile			
			310				315						320					
aat	gtc	agc	gac	tct	ggc	gcc	cag	agt	ttt	aag	atc	aac	gcc	ccc	tca	3806		
Asn	Val	Ser	Asp	Ser	Gly	Ala	Gln	Ser	Phe	Lys	Ile	Asn	Ala	Pro	Ser			
			325				330						335					
aac	cag	tcc	tac	cag	gtc	gag	cta	gcc	ctt	cca	ggg	gcg	ttc	aac	gtt	3854		
Asn	Gln	Ser	Tyr	Gln	Val	Glu	Leu	Ala	Leu	Pro	Gly	Ala	Phe	Asn	Val			
			340				345						355					
gct	aac	gcc	acg	ttg	gca	ttt	gcc	gct	gcg	gca	ccg	tgg	gtg	ttg	atg	3902		
Ala	Asn	Ala	Thr	Leu	Ala	Phe	Ala	Ala	Ala	Ala	Pro	Trp	Val	Leu	Met			
			360							365			370					
gcg	acg	ttt	gct	cga	ggc	atg	tcc	aag	gtc	gcg	gtt	cca	ggc	cgt	atg	3950		
Ala	Thr	Phe	Ala	Arg	Gly	Met	Ser	Lys	Val	Ala	Val	Pro	Gly	Arg	Met			
			375							380			385					
gaa	cgc	att	gat	gag	gga	caa	gac	ttc	ctt	gca	gtg	gtg	gat	tat	gcc	3998		
Glu	Arg	Ile	Asp	Glu	Gly	Gln	Asp	Phe	Leu	Ala	Val	Val	Asp	Tyr	Ala			
			390				395						400					
cac	aag	cct	gct	gca	gtg	gct	gct	gtg	ttg	gat	acg	ttg	agg	acc	cag	4046		
His	Lys	Pro	Ala	Ala	Val	Ala	Ala	Val	Leu	Asp	Thr	Leu	Arg	Thr	Gln			
			405				410						415					
att	gac	ggg	cgc	ctc	gga	agt	ggt	tat	cgg	tgc	tgg	tgg	aga	cgc	gat	4094		
Ile	Asp	Gly	Arg	Leu	Gly	Ser	Gly	Tyr	Arg	Cys	Trp	Trp	Arg	Arg	Asp			
			420				425						435					
tcc	acc	aag	cgt	ggc	ccc	atg	ggc	agt	tgt	ccg	cac	agg	tct	gga	tct	4142		
Ser	Thr	Lys	Arg	Gly	Pro	Met	Gly	Ser	Cys	Pro	His	Arg	Ser	Gly	Ser			
			440							445			450					
agt	tat	tgt	act	gat	gca	aac	ctc	gtc	aga	gtg	gct	ggc	acg	att	cgc	4190		
Ser	Tyr	Cys	Thr	Asp	Ala	Asn	Leu	Val	Arg	Val	Ala	Gly	Thr	Ile	Arg			
			455				460						465					
gca	gca	gtc	act	gca	gga	gca	cag	cag	ggt	gct	tca	gag	tcc	gaa	cga	4238		
Ala	Ala	Val	Thr	Ala	Gly	Ala	Gln	Gln	Gly	Ala	Ser	Glu	Ser	Glu	Arg			
			470				475						480					
ccg	gtg	gaa	gtc	cta	gaa	att	ggt	gac	cgt	gca	gaa	gca	att	cgc	gtt	4286		
Pro	Val	Glu	Val	Leu	Glu	Ile	Gly	Asp	Arg	Ala	Glu	Ala	Ile	Arg	Val			
			485				490						495					
ttg	gtc	gag	tgg	gca	cag	cct	gga	gat	ggc	att	gta	gta	gct	gga	aaa	4334		
Leu	Val	Glu	Trp	Ala														

ggc cat gaa gtt gga caa cta gtt gct ggt gtc acc cac cat ttt gat	4382
Gly His Glu Val Gly Gln Leu Val Ala Gly Val Thr His His Phe Asp	
520 525 530	
gac cgc gaa gaa ggt cgc gct gct ttg aca gaa aag ctc aac aat aaa	4430
Asp Arg Glu Glu Gly Arg Ala Ala Leu Thr Glu Lys Leu Asn Asn Lys	
535 540 545	
ctt ccc ctt act acg gaa gaa gga taggccacag tc atg atc aca atg acc	4481
Leu Pro Leu Thr Thr Glu Glu Gly Met Ile Thr Met Thr	
550 555 1	
ctt ggg gaa atc gct gac atc gtt gga ggc agg cta act ggc ggt gct	4529
Leu Gly Glu Ile Ala Asp Ile Val Gly Gly Arg Leu Thr Gly Gly Ala	
5 10 15 20	
caa gaa gat acg ctt gtg agc tcc agc gtg gaa ttt gat tct cga tcc	4577
Gln Glu Asp Thr Leu Val Ser Ser Ser Val Glu Phe Asp Ser Arg Ser	
25 30 35	
ctc aca ccg ggt ggc ttg ttt tta gca ctt ccg ggt gct cgt gta gac	4625
Leu Thr Pro Gly Gly Leu Phe Leu Ala Leu Pro Gly Ala Arg Val Asp	
40 45 50	
ggc cat gat ttt gct gca act gca att gag aaa ggt gcg gtc gca gta	4673
Gly His Asp Phe Ala Ala Thr Ala Ile Glu Lys Gly Ala Val Ala Val	
55 60 65	
ttg gca gcc cgt gag gtt gac gta cct gcg atc gtc gtg cct cca gta	4721
Leu Ala Ala Arg Glu Val Asp Val Pro Ala Ile Val Val Pro Pro Val	
70 75 80	
aaa atc cag gaa tcc aat gct gac att tat gct cat gaa cca gat ggg	4769
Lys Ile Gln Glu Ser Asn Ala Asp Ile Tyr Ala His Glu Pro Asp Gly	
85 90 95 100	
cat ggc gcg gcg gta gtg gag gcg ttg tct cgg ttg gct cgc cac gtg	4817
His Gly Ala Ala Val Val Glu Ala Leu Ser Arg Leu Ala Arg His Val	
105 110 115	
gtg gat atc tgc gtg gct ggc cat caa ttg aac gtt gtg gct att act	4865
Val Asp Ile Cys Val Ala Gly His Gln Leu Asn Val Val Ala Ile Thr	
120 125 130	
ggt tct gcg gga aag act tct acg aag gat ttc atc gcg acg gtt ctt	4913
Gly Ser Ala Gly Lys Thr Ser Thr Lys Asp Phe Ile Ala Thr Val Leu	
135 140 145	
ggc caa gat ggg cca act gtg gca cct ccg ggc tcg ttt aac aat gag	4961
Gly Gln Asp Gly Pro Thr Val Ala Pro Pro Gly Ser Phe Asn Asn Glu	
150 155 160	
ctt ggt ttg cca cac acc gtc cgc tgc aca acc gat act aag tat ttg	5009
Leu Gly Leu Pro His Thr Val Arg Cys Thr Thr Asp Thr Lys Tyr Leu	
165 170 175 180	
gtg gct gag atg tcc gcg cgt ggc att gga cat att aag cac ctg aca	5057
Val Ala Glu Met Ser Ala Arg Gly Ile Gly His Ile Lys His Leu Thr	

005000 "505000"

	185	190	195	
	gag att cgt ccg cca cgg att gca gct gtg ctc aac gtc ggc cat gcg Glu Ile Arg Pro Pro Arg Ile Ala Ala Val Leu Asn Val Gly His Ala 200 205 210			5105
	cac ctg ggt gaa ttt gga tcc cgc gag aat atc gcg cag gca aaa ggc His Leu Gly Glu Phe Gly Ser Arg Glu Asn Ile Ala Gln Ala Lys Gly 215 220 225			5153
	gag atc att gaa gcg ctg ccc tcg aag aaa acg ggt ggg gta gca gtc Glu Ile Ile Glu Ala Leu Pro Ser Lys Lys Thr Gly Gly Val Ala Val 230 235 240			5201
	ctt aac gct gac gat cct ttt gtc gcc cgg atg gct cca cgc act aag Leu Asn Ala Asp Asp Pro Phe Val Ala Arg Met Ala Pro Arg Thr Lys 245 250 255 260			5249
	gcg cgc gtg gtg tgg ttt acc acc gat gca ggc caa gca aaa aag tct Ala Arg Val Val Trp Phe Thr Thr Asp Ala Gly Gln Ala Lys Lys Ser 265 270 275			5297
	gat tat tgg gca acg agt att tca ctg gac gct gtt gcg cgg gca agc Asp Tyr Trp Ala Thr Ser Ile Ser Leu Asp Ala Val Ala Arg Ala Ser 280 285 290			5345
tt				5347
<210> 2				
<211> 581				
<212> PRT				
<213> Brevibacterium lactofermentum				
<400> 2				
Met Val Thr Arg Ile Ala Leu Val Ile Ala Gly Val Leu Ile Ile Arg 1 5 10 15				
Leu Gly Trp Val Gln Val Val Trp Gly Pro Glu Leu Ser Leu Asn Ala 20 25 30				
Ser Glu Gln Arg Thr Arg Val Tyr Val Asp Pro Ala Arg Arg Gly Thr 35 40 45				
Ile Val Asp Arg Glu Gly Asn Gln Met Ala Tyr Thr Met Gln Ala Arg 50 55 60				
Ser Leu Thr Val Ser Pro Asn Ile Met Arg Glu Glu Leu Lys Thr Gly 65 70 75 80				
Thr Asp Leu Ala Leu Arg Leu Ala Ala Glu Glu Thr Asp Pro Glu Asn 85 90 95				
Val Ala Ser Tyr Val Thr Ile Glu Glu Gly Asn Ala Tyr Val Phe Ala 100 105 110				
Ser Glu Glu Gln Arg Glu Thr Ile Leu Ser Asp Lys Val Glu Glu Arg 115 120 125				

005060"569e2960

Ile Gln Ser Ile Ala Asp Arg Ile Pro Glu Ile Ile Lys Ser His Asp
 130 135 140
 Gln Asp Val Thr Gly Ile Ser Ser Glu Glu Ile Leu Asp Lys Leu Asn
 145 150 155 160
 Ala Asp Ser Gln Tyr Glu Val Leu Val Arg Asn Val Asp Pro Asp Val
 165 170 175
 Ala Ser Glu Ile Thr Asp Glu Met Pro Ser Val Ala Ala Asp His Gln
 180 185 190
 Asp Ile Arg Gln Tyr Pro Asn Gly Ala Ile Gly Glu Asn Ile Ile Gly
 195 200 205
 Arg Ile Ser Met Asp Gly Glu Gly Gln Phe Gly Phe Glu Ala Ser Asn
 210 215 220
 Asp Ser Leu Leu Ala Gly Asn Asn Gly Arg Ser Thr Gln Asp Met Ser
 225 230 235 240
 Ile Leu Gly Gln Ala Ile Pro Gly Thr Leu Arg Asp Gln Ile Pro Ala
 245 250 255
 Ile Asp Gly Ala Ser Val Glu Leu Thr Val Asp Leu Asp Leu Gln Thr
 260 265 270
 Tyr Val Gln Gln Ala Leu Glu Gln Ala Lys Ala Asn Ser Gly Ala Glu
 275 280 285
 Asn Ala Ser Ala Val Val Leu Asp Ala Glu Thr Ala Glu Val Leu Ala
 290 295 300
 Met Ala Asn Thr Asp Thr Ile Asn Pro Asn Glu Asp Thr Gly Lys Gln
 305 310 315 320
 Ile Glu Gln Gly Lys Ser Phe Asp Asn Pro Ser Val Thr His Pro Phe
 325 330 335
 Glu Pro Gly Ser Val Ala Lys Val Ile Thr Ala Ala Gly Val Ile Gln
 340 345 350
 Asp Gly Leu Thr Thr Pro Asp Glu Val Leu Gln Val Pro Gly Ser Ile
 355 360 365
 Glu Met Ala Gly Val Ser Val Gly Asp Ala Trp Asp His Gly Val Val
 370 375 380
 Pro Tyr Thr Thr Ala Gly Ile Phe Gly Lys Ser Ser Asn Val Gly Thr
 385 390 395 400
 Leu Met Leu Ala His Gly Leu Gly Glu Asp Lys Phe Ala Asp Tyr Leu
 405 410 415
 Glu Arg Phe Gly Val Gly Gln Ser Thr Gly Ile Glu Leu Pro Ser Glu
 420 425 430

005000" 93322300

```

<400> 3
Val Ser Phe Val Glu Phe His Asn Leu Asn Phe Cys Leu Asn Ser Phe
  1          5          10
Arg His His Pro Arg Ala Ala Ser Glu Leu Leu Thr Pro Arg Asn Leu
      20          25          30
Trp Arg Arg Glu Asn His Gly Asn His Val Ala Gly Pro His Gln Thr
      35          40          45
Tyr Arg Trp His Pro Gln Gly Leu Cys Gln Gly Val Pro Ala His Ala
      50          55          60
Val Gly Glu Gln Ala Ile Ala Ala Ile Gly Leu Asp Ser Ser Ser Leu
      65          70          75
Pro Thr Ser Asp Ala Ile Phe Ala Ala Val Pro Gly Thr Arg Thr His
      85          90          95
Gly Ala Gln Phe Ala Gly Thr Asp Asn Ala Ala Lys Ala Val Ala Ile
      100          105          110

```

Leu Thr Asp Ala Ala Gly Leu Glu Val Leu Asn Glu Ala Gly Glu Thr
 115 120 125
 Arg Pro Ile Ile Val Val Asp Asp Val Arg Ala Val Leu Gly Ala Ala
 130 135 140
 Ser Ser Ser Ile Tyr Gly Asp Pro Ser Lys Asp Phe Thr Leu Ile Gly
 145 150 155 160
 Val Thr Gly Thr Ser Gly Lys Thr Thr Thr Ser Tyr Leu Leu Glu Lys
 165 170 175
 Gly Leu Met Glu Ala Gly His Lys Val Gly Leu Ile Gly Thr Thr Gly
 180 185 190
 Thr Arg Ile Asp Gly Glu Glu Val Pro Thr Lys Leu Thr Thr Pro Glu
 195 200 205
 Ala Pro Thr Leu Gln Ala Leu Phe Ala Arg Met Arg Asp His Gly Val
 210 215 220
 Thr His Val Val Met Glu Val Ser Ser His Ala Leu Ser Leu Gly Arg
 225 230 235 240
 Val Ala Gly Ser His Phe Asp Val Ala Ala Phe Thr Asn Leu Ser Gln
 245 250 255
 Asp His Leu Asp Phe His Pro Thr Met Asp Asp Tyr Phe Asp Ala Lys
 260 265 270
 Ala Leu Phe Phe Arg Ala Asp Ser Pro Leu Val Ala Asp Lys Gln Val
 275 280 285
 Val Cys Val Asp Asp Ser Trp Gly Gln Arg Met Ala Ser Val Ala Ala
 290 295 300
 Asp Val Gln Thr Val Ser Thr Leu Gly Gln Glu Ala Asp Phe Ser Ala
 305 310 315 320
 Thr Asp Ile Asn Val Ser Asp Ser Gly Ala Gln Ser Phe Lys Ile Asn
 325 330 335
 Ala Pro Ser Asn Gln Ser Tyr Gln Val Glu Leu Ala Leu Pro Gly Ala
 340 345 350
 Phe Asn Val Ala Asn Ala Thr Leu Ala Phe Ala Ala Ala Ala Pro Trp
 355 360 365
 Val Leu Met Ala Thr Phe Ala Arg Gly Met Ser Lys Val Ala Val Pro
 370 375 380
 Gly Arg Met Glu Arg Ile Asp Glu Gly Gln Asp Phe Leu Ala Val Val
 385 390 395 400
 Asp Tyr Ala His Lys Pro Ala Ala Val Ala Ala Val Leu Asp Thr Leu
 405 410 415
 Arg Thr Gln Ile Asp Gly Arg Leu Gly Ser Gly Tyr Arg Cys Trp Trp

005000 "SAS" 005000

420 425 430
 Arg Arg Asp Ser Thr Lys Arg Gly Pro Met Gly Ser Cys Pro His Arg
 435 440 445
 Ser Gly Ser Ser Tyr Cys Thr Asp Ala Asn Leu Val Arg Val Ala Gly
 450 455 460
 Thr Ile Arg Ala Ala Val Thr Ala Gly Ala Gln Gln Gly Ala Ser Glu
 465 470 475 480
 Ser Glu Arg Pro Val Glu Val Leu Glu Ile Gly Asp Arg Ala Glu Ala
 485 490 495
 Ile Arg Val Leu Val Glu Trp Ala Gln Pro Gly Asp Gly Ile Val Val
 500 505 510
 Ala Gly Lys Gly His Glu Val Gly Gln Leu Val Ala Gly Val Thr His
 515 520 525
 His Phe Asp Asp Arg Glu Glu Gly Arg Ala Ala Leu Thr Glu Lys Leu
 530 535 540
 Asn Asn Lys Leu Pro Leu Thr Thr Glu Glu Gly
 545 550 555

 <210> 4
 <211> 293
 <212> PRT
 <213> Brevibacterium lactofermentum

 <400> 4
 Met Ile Thr Met Thr Leu Gly Glu Ile Ala Asp Ile Val Gly Gly Arg
 1 5 10 15
 Leu Thr Gly Gly Ala Gln Glu Asp Thr Leu Val Ser Ser Ser Val Glu
 20 25 30
 Phe Asp Ser Arg Ser Leu Thr Pro Gly Gly Leu Phe Leu Ala Leu Pro
 35 40 45
 Gly Ala Arg Val Asp Gly His Asp Phe Ala Ala Thr Ala Ile Glu Lys
 50 55 60
 Gly Ala Val Ala Val Leu Ala Ala Arg Glu Val Asp Val Pro Ala Ile
 65 70 75 80
 Val Val Pro Pro Val Lys Ile Gln Glu Ser Asn Ala Asp Ile Tyr Ala
 85 90 95
 His Glu Pro Asp Gly His Gly Ala Ala Val Val Glu Ala Leu Ser Arg
 100 105 110
 Leu Ala Arg His Val Val Asp Ile Cys Val Ala Gly His Gln Leu Asn
 115 120 125
 Val Val Ala Ile Thr Gly Ser Ala Gly Lys Thr Ser Thr Lys Asp Phe

005560 5352560

130 135 140
 Ile Ala Thr Val Leu Gly Gln Asp Gly Pro Thr Val Ala Pro Pro Gly
 145 150 155 160
 Ser Phe Asn Asn Glu Leu Gly Leu Pro His Thr Val Arg Cys Thr Thr
 165 170 175
 Asp Thr Lys Tyr Leu Val Ala Glu Met Ser Ala Arg Gly Ile Gly His
 180 185 190
 Ile Lys His Leu Thr Glu Ile Arg Pro Pro Arg Ile Ala Ala Val Leu
 195 200 205
 Asn Val Gly His Ala His Leu Gly Glu Phe Gly Ser Arg Glu Asn Ile
 210 215 220
 Ala Gln Ala Lys Gly Glu Ile Ile Glu Ala Leu Pro Ser Lys Lys Thr
 225 230 235 240
 Gly Gly Val Ala Val Leu Asn Ala Asp Asp Pro Phe Val Ala Arg Met
 245 250 255
 Ala Pro Arg Thr Lys Ala Arg Val Val Trp Phe Thr Thr Asp Ala Gly
 260 265 270
 Gln Ala Lys Lys Ser Asp Tyr Trp Ala Thr Ser Ile Ser Leu Asp Ala
 275 280 285
 Val Ala Arg Ala Ser
 290

<210> 5
 <211> 30
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 5
 gcgcgaattc cgcaacctcg tcgtgacatg 30

<210> 6
 <211> 340
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:primer

<400> 6
 gcgcgaattc aagaccaata gccgcgattg cttg 34

005060 3652360